78 completed. 78 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 78 | Completed 78 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin Unfractionated heparin, Double-legged cycle ergometer exercise, Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg - Blood Coagulation Disorder | Phase 4 | Completed | Kristian Karstoft | 23 | 2023-09-22 | 2024-06-26 |
| Bridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and Pain Post-Liposuction Carboxytherapy, Placebo - Liposuction, Bruising | Phase 4 | Completed | Total Definer Research Group | 72 | 2023-09-01 | 2026-07-21 |
| Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate - Hypofibrinogenemia, Bleeding | Phase 4 | Completed | Weill Medical College of Cornell University | 208 | 2023-04-01 | 2025-11-21 |
| A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts rhTPO, Eltrombopag - Previously Treated Primary Immune Thrombocytopenia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 157 | 2022-11-22 | 2025-04-24 |
| Prophylaxis Regimen for Hemophilia A Patients Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG). - Hemophilia A, Prophylaxis of Bleeding | Phase 4 | Completed | Bayer | 21 | 2022-07-28 | 2025-11-12 |
| Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis, pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone - Hemophilia | Phase 4 | Completed | Chulalongkorn University | 13 | 2022-07-01 | 2023-02-15 |
| Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery Fibrinogen Concentrate Human - Fibrinogen, Spine Deformity | Phase 4 | Completed | Brno University Hospital | 32 | 2022-06-06 | 2026-10-16 |
| Intensive Replacement Treatment in Haemophilia Patients With Synovitis EHL-FVIII, FVIII concentrate - Hemophilia A | Phase 4 | Completed | Federico II University | 64 | 2022-03-01 | 2024-03-27 |
| EFFECTS OF TRANEXAMIC ACID IN TUMESCENT SOLUTION FOR LIPOSUCTION PROCEDURES Tranexamic Acid (Topical), Tumescent solution with dilute lidocaine and epinephrine - Liposuction, Bruising | Phase 4 | Completed | Total Definer Research Group | 78 | 2022-01-20 | 2025-04-30 |
| A Study of ADVATE in People With Hemophilia A in India ADVATE - Hemophilia A | Phase 4 | Completed | Baxalta now part of Shire | 50 | 2022-01-14 | 2024-03-07 |
| Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A Extended half-life FVIII concentrates with PK-guided dosing, standard half-life FVIII concentrates with weight-based dosing - Severe Hemophilia A Without Inhibitor | Phase 4 | Completed | Chulalongkorn University | 15 | 2021-07-01 | 2022-07-20 |
| Topical Tranexamic Acid Application in Rhinoplasty Tranexamic acid, Isotonic saline - Ecchymosis; Eyelid, Edema | Phase 4 | Completed | Baskent University | 50 | 2021-06-07 | 2022-04-13 |
| Health Related Quality of Life of Youth and Young Adults With Haemophilia A Efmoroctocog Alfa Injection [Eloctate] - Hemophilia A | Phase 4 | Completed | The League of Clinical Research, Russia | 30 | 2021-04-15 | 2023-12-12 |
| Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim Avatrombopag Oral Tablet - Immune Thrombocytopenia | Phase 4 | Completed | Sobi, Inc. | 60 | 2021-03-15 | 2025-01-16 |
| A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3 - Hemophilia A | Phase 4 | Completed | Bayer | 45 | 2020-09-22 | 2025-04-18 |
| Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B Nonacog alfa - Hemophilia B | Phase 4 | Completed | Pfizer | 25 | 2020-02-10 | 2022-07-01 |
| Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients Moroctocog-alfa (AF-CC) - Hemophilia A | Phase 4 | Completed | Pfizer | 50 | 2020-01-25 | 2021-05-03 |
| Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Damoctocog alfa pegol (Jivi, BAY94-9027) - Hemophilia A | Phase 4 | Completed | Bayer | 32 | 2019-09-23 | 2023-07-27 |
| RIXUBIS PMS India (RIXUBIS PMS) RIXUBIS: On-Demand, RIXUBIS: Prophylaxis - Hemophilia B | Phase 4 | Completed | Baxalta now part of Shire | 25 | 2018-12-07 | 2022-08-30 |
| NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers Edoxaban 60 MG - Blood Coagulation Disorder | Phase 4 | Completed | Turku University Hospital | 15 | 2018-11-26 | 2019-09-17 |
Showing 20 of 78. Sign in to see all of them.
Hemophilia A (38) · Purpura, Thrombocytopenic, Idiopathic (11) · Hemophilia B (10) · Hemorrhage (4) · Hemostatic Disorders (4) · Thrombocytopenia (4) · Afibrinogenemia (3) · Contusions (3) · Ecchymosis (3) · Purpura (3) · Thrombocythemia, Essential (3) · Blood Platelet Disorders (2) · Bruton type agammaglobulinemia (2) · Disseminated Intravascular Coagulation (2)
Hemic and Lymphatic Diseases (78) · Hematologic Diseases (76) · Hemorrhagic Disorders (67) · Blood Coagulation Disorders, Inherited (51) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (51) · Genetic Diseases, Inborn (51) · Coagulation Protein Disorders (49) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Hemorrhage (18) · Signs and Symptoms (17) · Skin Manifestations (17) · Immune System Diseases (16) · Blood Platelet Disorders (15)
Factor VIII (19) · F8 protein, human (8) · Factor IX (4) · BAY 14-2222 (3) · Fibrinogen (3) · eltrombopag (3) · Clinical Laboratory Techniques (2) · Dexamethasone (2) · Sodium Chloride (2) · Tranexamic Acid (2) · Warfarin (2) · factor VIII-Fc fusion protein (2) · gamma-Globulins (2) · recombinant FVIII, sugar formulated (2) · recombinant factor VIII SQ (2)
Baxalta now part of Shire (9) · Bayer (7) · Pfizer (6) · CSL Behring (3) · Chulalongkorn University (3) · Shandong University (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Novartis Pharmaceuticals (2) · Total Definer Research Group (2) · University of Sao Paulo General Hospital (2) · Amgen (1) · Asahi Kasei Therapeutics Corporation (1) · Assiut University (1) · Baqiyatallah Medical Sciences University (1) · Baskent University (1)
United States (19) · China (10) · Italy (10) · France (8) · Poland (8) · India (7) · Russia (7) · Spain (7) · United Kingdom (7) · Germany (6) · Brazil (5) · Bulgaria (5) · Greece (5) · Romania (5) · Sweden (5)
Alfredo E Hoyos, MD (1) · Andrew C Frisina, MS (1) · Bashir HajiBeigi, M.D. (1) · Bernard Boneu, MD (1) · Bita Behnava, M.D. (1) · Brian Berman, MD, PhD (1) · Brian M Feldman, MD (1) · Christopher Tirotta, MD (1) · Darintr Sosothikul, MD (1) · David O Meltzer, MD, PhD (1)
PMID 20546023, PMID 21626222, PMID 21674758, PMID 21710166, PMID 22212248, PMID 23293082, PMID 23389750, PMID 24254965, PMID 25296772, PMID 25982134, PMID 26480931, PMID 27040278, PMID 27223147, PMID 28768627, PMID 29731369, PMID 30368038, PMID 33123978, PMID 33269010, PMID 34032739, PMID 34215519, PMID 34755760, PMID 35049070, PMID 35305111, PMID 36409282, PMID 36818468, PMID 36853224, PMID 37236666, PMID 37735543, PMID 38532451, PMID 39334317, PMID 39583653, PMID 40101243, PMID 40846660, PMID 40896456, PMID 41062134, PMID 41886249, PMID 8217798
2008 (3), 2009 (3), 2005 (2), 2014 (2), 2017 (2), 2004 (1), 2015 (1), 2016 (1), 2018 (1), 2023 (1)